Choices Drug Therapies
|
|
- Britton Carter
- 8 years ago
- Views:
Transcription
1 Choices Drug Therapies There are many prescription drugs available to treat MS. There are disease modifying drugs that affect the long-term course of MS and other medications to treat a particular symptom. Disease Modifying Treatments (DMTs) There are number of disease-modifying treatments (DMTs) which can reduce the frequency and severity of clinical relapses. The National Institution for Care Excellence (NICE) published guidelines in October 2014 for the management of multiple sclerosis. In these guidelines a relapse can be diagnosed by a GP or neurologist if: The person with MS has developed new symptoms or has a worsening of existing symptoms, and these symptoms have lasted for more than 24 hours in the absence of infection of any other cause after a stable period of a least 1 month. The following DMTs are available for treatment of relapsing remitting multiple sclerosis, CIS and secondary progressive MS who are still experiencing relapses, and where these relapses are the predominant cause of their increasing disability :- Avonex - a weekly injection into the muscle. Rebif an injection three times a week subcutaneously (under the skin). Betaferon an injection every other day subcutaneously (under the skin). Extavia an injection every other day subcutaneously (under the skin). Glatiramer acetate (Copaxone) - a daily injection subcutaneously (under the skin). The following DMTs are additionally available for treatment of relapsing remitting multiple sclerosis: Fingolimod (Gilenya) - an oral tablet taken once a day. Tecfidera (Dimethyl fumerate) - an oral tablet twice a day. Teriflunomide (Aubagio) - taken orally once a day. For more detailed information about DMTs, please see our Choices leaflet Disease Modifying Treatments.
2 Tysabri (Natalizumab) A monoclonal antibody that works in a different way to the above DMTs, by preventing immune cells leaving the blood stream and entering areas of inflammation. This is available for people on the NHS with rapidly evolving, severe relapsing remitting MS. Rapidly evolving, severe RRMS is defined by two or more disabling relapses in one year along with an increase of lesions as shown on an MRI. Tysabri is a once a month intravenous infusion into a vein over a one hour period in a registered infusion facility. For more detailed information about Tysabri, please see our Choices leaflet Tysabri. Alemtuzumab (Campath/Lemtrada) Alemtuzumab was originally licensed for the treatment of leukaemia. It is an anti-cd52 monoclonal antibody which kills T-cells, a type of lymphocyte involved in the MS immune response. It basically reboots the immune system. Once the t-cells are killed (lymphocytes) the system then repopulates, leading to a modified immune response that no longer regards myelin and nerves as foreign. The drug received NICE appraisal as an NHS treatment in May 2014 from NICE and in July 2014 from the Scottish Medicines Consortium (SMC). Other Drugs used in MS Low Dose Naltrexone (LDN) LDN has been used in the treatment of MS in the USA since 1985 but it is relatively new in the United Kingdom. Naltrexone is a drug referred to as an opiate antagonist. Its normal use is to treat opiate drug addicts addicted to drugs such as heroin; however when taken to treat MS, the dose is much smaller. Those taking it have experienced a range of benefits, including reduced spasm and fatigue, improvements in bladder control, heat tolerance, mobility, sleep, pain, tremor and other symptoms. The two main symptoms that appear to improve most significantly are muscle spasm and fatigue. It is not recognised by the NHS as a proven treatment for MS symptoms and may not therefore be prescribed by a GP or neurologist easily. It can be purchased privately in the UK. For more information about LDN, please see our Choices leaflet LDN.
3 Mitoxantrone (Novantrone) Licensed in the UK as a form of chemotherapy used in cancer treatment but can be used to treat some forms of MS. Usually given to people who have not responded to Copaxone or any of the Interferons. It is given at the Neurologist s discretion by intravenous infusion. Steroids Steroids are sometimes used when a person experiences a relapse to help speed recovery. Steroids can reduce inflammation in the CNS. They are usually administered intravenously but sometimes orally. In short term use, side-effects are usually minor. Long term use should be avoided as this can cause many side-effects including weight gain, acne and cataracts. For this reason, NICE guidelines recommend only using steroids three times a year. Fampridine (Fampyra/Ampyra) This drug therapy is a formulation of 4-aminopyridine a potassium channel blocker. It is thought that it can enhance the conduction of messages in damaged nerve fibres by blocking potassium leaks. It is generally prescribed for people with MS who have MS related mobility problems. Taken twice a day, fampridine is a licensed treatment to improve walking speed. Fampridine is not recommended by the Scottish Medicines Consortium (SMC). In October 2014 the National Institute of Care Excellence published clinical guidelines for the treatment of multiple sclerosis. In these guidelines, NICE states that fampridine should not be offered to treat a lack of mobility in people with MS. This recommendation does not apply to people who have already started treatment with fampridine in the NHS who should be able to continue treatment until they and their NHS clinician think it appropriate to stop. Drugs in development and trial The average time it takes for a new compound to get from the test tube to be licensed is 10 to 15 years. It is important to remember that not all these drugs will complete the development process and be licensed for general use or be recommended by NICE (National Institute for Health and Care Excellence) or the SMC (Scottish Medicines Consortium) ATX-MS-1467 Daclizumab
4 Masitinib Laquinimod Ocrelizumab Natalizumab Ofatumumab Siponimod Tovaxin Drugs used to manage symptoms Bladder Dysfunction see our Choices leaflet Bladder & Bowel for further information. Oxybutynin Oxybutynin is used to control urgent, frequent, or uncontrolled urination in people who have overactive bladder (a condition in which the bladder muscles have uncontrollable spasms) or other conditions that affect the bladder muscles. Oxybutynin is in a class of medications called anticholinergics. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Desmopressin Desmopressin is a synthetic antidiuretic hormone, which basically means that it supresses the production of urine in the kidneys by up to 8 hours. It is used to help relieve urinary incontinence in conditions such as MS. More specifically, it is used for those who experience nocturia, the need to frequently go to the toilet at night. It can also be used during the day if finding a toilet may be difficult. For example, on a long journey. It should not be over-used due to the dangers of retaining too much urine. Detrusitol (Tolterodine) Tolterodine is used to relieve urinary difficulties, including frequent urination and inability to control urination. Tolterodine is in a class of medications called antimuscarinics. It works by preventing bladder contraction. Botox Botulinum toxin type A (Botox) is best known as a cosmetic treatment for facial wrinkles. Doctors have also found that botulinum toxin is useful in blocking spasms like eye ticks or relaxing muscles in patients with multiple sclerosis. Urologists have found that injecting botulinum toxin into the tissue surrounding the sphincter can help it to relax. Botox for the bladder was approved by the MHRA in September 2012 for those who have failed on existing treatments such as anticholinergics. Fatigue see our Choices leaflet Fatigue for further information.
5 Amantadine Amantadine is used to treat Parkinson's disease and conditions similar to those of Parkinson's disease. This medication is sometimes prescribed for other uses such as fatigue in multiple sclerosis. Spasticity - see our Choices leaflet Symptoms for further information. Baclofen Baclofen acts on the spinal cord nerves and decreases the number and severity of muscle spasms caused by multiple sclerosis or spinal cord diseases. It also relieves pain and improves muscle movement. Dantrolene Dantrolene is used to treat chronic (long-term) muscle spasm or spasticity. Longterm muscle stiffness can occur in multiple sclerosis and other conditions where there has been damage to the nerves that supply the muscles. In these cases, muscles may contract (or shorten) tightly, they can then become stiff and harder to use. This is called spasticity. Dantrolene works by relaxing the muscles and preventing spasms. This helps to reduce any pain and discomfort. Diazepam Diazepam is a type of medicine called a benzodiazepine. Benzodiazepines are used for their sedative, anxiety-relieving and muscle-relaxing effects. Diazepam works by acting on receptors in the brain called GABA receptors. This causes the release of a neurotransmitter called GABA in the brain. Botox See above Tizanidine (Zanaflex) Zanaflex tablets contain the active ingredient tizanidine, which is a type of medicine known as an alpha-2-adrenoceptor agonist. Tizanidine is used as a muscle relaxant, in conditions such as multiple sclerosis and spinal cord injury or disease. Sativex Sativex is a cannabis-based medicine used by people with MS for spasticity, when first line drugs have been ineffective or where side effects of those drugs are intolerable. It is an oral-mucosal spray into the mouth, under the tongue or inside of the cheeks. The number of sprays or timings of these sprays varies dependent on severity of symptoms and will be confirmed by the prescribing doctor. The maximum number of sprays a day is 12 and a gap of at least 15 minutes should be left between sprays. The most common side effects are dizziness, fatigue, drowsiness and nausea.
6 In October 2014 the National Institute of Care Excellence published clinical guidelines for the treatment of multiple sclerosis. In these guidelines, NICE states that Sativex should not be offered to treat spasticity in people with MS. Sativex may still be available through the NHS if funding is secured through an Individual Funding Request, although such a request is less likely to be successful in the light of the NICE guidelines. Sativex can be purchased privately if a private prescription is obtained from a GP. Tremor see our Choices leaflet on Symptoms for further information. Propranolol Syprol oral solution contains the active ingredient propranolol, which is a type of medicine called a beta-blocker. Beta-blockers work by blocking beta receptors that are found in various parts of the body. Blocking beta receptors prevents the action of two chemicals, called noradrenaline and adrenaline, which are produced naturally by the body. Beta-blockers may have some effect on reducing MS related tremor. Primidone (Mysoline) Primidone is a medicine which is used in partial epilepsy, generalised epilepsy, myoclonus and essential tremor. Mysoline tablets contain the active ingredient primidone. Clonazepam (Rivotril) Rivotril tablets and injections both contain clonazepam, which is a type of medicine called a benzodiazepine. Clonazepam is also available without a brand name, i.e. as the generic medicine. Clonazepam acts on nerve cells in the brain. Clonidine Clonidine is thought to reduce the responsiveness of small blood vessels to stimuli which would normally make them contract (narrow) or dilate (widen). This prevents the changes in the blood vessels of the brain which are associated with migraine, and thus prevents attacks. Pain see our Choices leaflet on Pain for further information. Gabapentin The way in which gabapentin works is not fully understood. It is thought to work by binding to calcium channels found on nerve cells in the brain and spinal cord. This is thought to affect the release of various neurotransmitters from these nerve cells.
7 Pregabalin The way in which pregabalin works is not fully understood. It is thought to work by binding to calcium channels found on nerve cells in the brain and spinal cord. This reduces the release of various neurotransmitters from these nerve cells. Carbamazepine Carbamazepine is an anticonvulsant. It works by decreasing nerve impulses that cause seizures and pain. Carbamazepine is used to treat seizures and nerve pain such as trigeminal neuralgia and diabetic neuropathy. It is also used to treat bipolar disorder. Amitriptyline Amitriptyline is a tricyclic antidepressant. It affects chemicals in the brain that may become unbalanced. Amitriptyline is used to treat symptoms of depression. Duloxetine Duloxetine is a serotonin-norepinephrine reuptake inhibitor, affecting chemicals in the brain that may be unbalanced. Duloxetine is used to treat symptoms of depression and generalised anxiety disorder, but can relieve the symptoms of neuropathic pain. Erectile Dysfunction see our Choices leaflet on Sexual Dysfunction for further information. Cialis Cialis (Tadalafil) relaxes muscles and increases blood flow to particular areas of the body. Cialis is used to treat erectile dysfunction (impotence) in men. Viagra Viagra (sildenafil) relaxes muscles and increases blood flow to particular areas of the body. Viagra is used to treat erectile dysfunction (impotence) in men. Levitra Levitra (Vardenafil) is a phosphodiesterase inhibitor. It works by helping to relax muscles and increase blood flow into the penis during sexual stimulation. This helps men to achieve and maintain an erection. Levitra is used to treat erectile dysfunction (impotence). Updated October 2014
A neurologist would assess your eligibility and suitability for the DMTs.
Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.
More informationChoices Primary Progressive MS (PPMS)
Choices Primary Progressive MS (PPMS) What is primary progressive MS? Approximately 10% of people with MS worldwide are told they have primary progressive MS a form of MS where from the very first symptoms,
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationInformation About Medicines for Multiple Sclerosis
Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationInformation about medicines for multiple sclerosis
Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain
More informationDisease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
More informationSymptomatic Treatment of MS Symptomatic treatments approved for use in patients with MS
Symptomatic Treatment of MS Symptomatic treatments approved for use in patients with MS Generic name Market name Symptoms Indicated Baclofen Lioresal Spasticity, cramps, stiffness Tizanidine Zanaflex Same
More informationNational Hospital for Neurology and Neurosurgery. Managing Spasticity. Spasticity Service
National Hospital for Neurology and Neurosurgery Managing Spasticity Spasticity Service If you would like this document in another language or format, or require the services of an interpreter please contact
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To
More informationNew treatments in MS What s here and what s nearly here
5 th MS Research Day, June 14 th 2014 New treatments in MS What s here and what s nearly here David Miller Queen Square MS Centre at UCL and UCLH Course of MS and its treatment Relapsing remitting Disability
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationMultiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.
What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationMultiple Sclerosis. Multiple Sclerosis. In addition to help nursing professional to understand the signs and
How to Receive Your CE Credits Read your selected course Completed the quiz at the end of the course with a 70% or greater. Complete the evaluation for your selected course. Print your Certificate CE s
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationDisease Modifying Therapies (DMTs) in Multiple Sclerosis
Disease Modifying Therapies (DMTs) in Multiple Sclerosis Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology Conflict of Interest Dr. Stobbe has no conflicts of
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationErectile Dysfunction (ED)
Information from your Patient Aligned Care Team What is Erectile Dysfunction or ED? Erectile dysfunction (also known as impotence) is the inability to get and keep an erection firm enough for sex. Having
More informationMultiple sclerosis disease-modifying drugs second line treatments
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction
More informationIntegrating New Treatments: A Case Based Approach
Integrating New Treatments: A Case Based Approach JILL CONWAY, MD, MA, MSCE DIRECTOR, MS CENTER DIRECTOR, NEUROLOGY CLERKSHIP AT UNCSOM- CHARLOTTE CAMPUS CAROLINAS HEALTHCARE CENTER Objectives Provide
More informationMedication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014
Medication Policy Manual Policy No: dru376 Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective
More informationThere's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationWhat is Multiple Sclerosis? Gener al information
What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal
More informationNovel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?
Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International
More informationDisease modifying drug therapy
Disease modifying drug therapy New edition for 2014-15 We hope you find the information in this book helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information
More informationNHS BOURNEMOUTH AND POOLE AND NHS DORSET
NHS BOURNEMOUTH AND POOLE AND NHS DORSET COMMISSIONING STATEMENT ON THE USE OF BETA-INTERFERON IN RELAPSING-REMITTING MULTIPLE SCLEROSIS OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, WHERE RELAPSES ARE
More informationFor example, MS can affect the way you move your body. You may at times find it hard to reach out for something or to walk properly.
Patient information from the BMJ Group Multiple sclerosis In this section What are the symptoms? How is it diagnosed? How common is it? What treatments work? What will happen? Questions to ask Multiple
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationUnderstandi your multipl sclerosis medications URAC. All Walgreens specialty pharmacy locations are ACHC and URAC accredited.
Understandi your multipl sclerosis medications URAC All Walgreens specialty pharmacy locations are ACHC and URAC accredited. Table of contents Multiple sclerosis medications: an overview...1 Staying on
More informationSativex (nabiximols)
Sativex (nabiximols) We hope you find the information in this factsheet helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information team and they will help
More informationSymptomatic management of multiple sclerosis in primary care
summarising clinical guidelines for primary care Endorsed by Symptomatic management of multiple sclerosis in primary care This guideline was developed by a multidisciplinary expert panel: Rashid W et al
More informationStudy Support Materials Cover Sheet
Study Support Materials Cover Sheet Document Title ESCALATE Patient Brochure Intended Audience This brochure is designed to be given to potentially eligible patients as a take-home summary of key information
More informationTreatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )
Treatments for MS: Immunotherapy There are currently several disease-modifying therapies approved for people with MS in Australia. These therapies, called immunotherapies, work to reduce disease activity
More informationMedications for MULTIPLE SCLEROSIS Student Version
Medications for MULTIPLE SCLEROSIS Student Version DEH 2300 Valencia Community College Summer: 2006-14 Sandra C. Pendergraft DEFINITION / PATHOPHYSIOLOGY Chronic, frequently progressive disease of CNS
More informationTeriflunomide (Aubagio)
Teriflunomide (Aubagio) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would like to speak
More informationMultiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationMultiple Sclerosis Drug Discoveries - What the Future Holds
Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally
More informationNew Treatment Options for MS Patients: Understanding risks versus benefits
New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationThe MS Disease- Modifying Drugs. Gener al information
The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationStepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU
FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your
More informationMedication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010
Medication Policy Manual Policy No: dru229 Topic: Gilenya, fingolimod Date of Origin: November 22, 2010 Committee Approval Date: December 11, 2015 Next Review Date: December 2016 Effective Date: January
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationRecruitment Start date: April 2010 End date: Recruitment will continue until enrolment is fully completed
Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has
More informationMultiple Sclerosis: What You Need To Know. For Professionals
Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought
More informationHow to S.E.A.R.C.H. SM for the Right MS Therapy For You!
How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration
More informationPatient Group Input to CADTH
Patient Group Input to CADTH Section 1 General Information Name of the drug CADTH is reviewing and indication(s) of interest Name of patient group/author of submission Patient group s contact information:
More informationMedication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004
Medication Policy Manual Policy No: dru108 Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationUnderstanding your Tecfidera treatment
Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS
More informationMichelle H. Cameron, M.D., P.T., M.C.R. Portland VA MS Center of Excellence- West, and Oregon Health & Science University
Michelle H. Cameron, M.D., P.T., M.C.R. Portland VA MS Center of Excellence- West, and Oregon Health & Science University Ileana Howard, M.D. VA Puget Sound, Seattle, WA and University of Washington PVA
More informationA Definition of Multiple Sclerosis
English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:
More informationNational Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013
National Multiple Sclerosis Society Disease Modification in Multiple Sclerosis Current as of January 2, 2013 Since 1993, the U.S. Food and Drug Administration (FDA) has approved several medications for
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of November 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationteriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.
teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd. 10 January 2014 (Issued 07 February 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationThe MS Disease- Modifying Medications GENERAL INFORMATION
The MS Disease- Modifying Medications GENERAL INFORMATION Current as of March 2014. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationBOTOX Treatment. for Chronic Migraine. Information for patients and their families. Botulinum Toxin Type A
BOTOX Treatment Botulinum Toxin Type A for Chronic Migraine Information for patients and their families. Is Chronic Migraine the same as Migraine? Chronic Migraine is similar to migraine as sufferers experience
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationCNS DEMYLINATING DISORDERS
CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such
More informationHow to S.E.A.R.C.H. for the Right MS Therapy for You!
How to S.E.A.R.C.H. for the Right MS Therapy for You! How to S.E.A.R.C.H. for the Right MS Therapy for You! Copyright Multiple Sclerosis Association of America, 2012. All rights reserved. This booklet
More informationDisease modifying drug therapy
Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about
More informationGrowth in revenue from MS drugs has been driven largely by price increases over the last several years.
March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera
More informationTreatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD
Treatment in Relapsing MS: Choosing Among the Options Donald Negroski, MD Disclosures Research Grants Educational activities and lectures Consulting or other services including Continuing Medical Education
More informationIncontinence. What is incontinence?
Incontinence What is incontinence? Broadly speaking, the medical term incontinence refers to any involuntary release of bodily fluids, but many people associate it strongly with the inability to control
More informationWebinar title: Know Your Options for Treating Severe Spasticity
Webinar title: Know Your Options for Treating Severe Spasticity Presented by: Dr. Gerald Bilsky, Physiatrist Medical Director of Outpatient Services and Associate Medical Director of Acquired Brain Injury
More informationManaging MS, Managing spasticity: People with MS experiences of Sativex
Managing MS, Managing spasticity: People with MS experiences of Sativex Diane Redfern-Tofts Multiple Sclerosis Society October 2014 1 Contents Introduction... 3 Method... 3 Questionnaire design... 3 Respondents...
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 08/2015 Origination: 08/2015 Next Review: 08/2016 Policy BCBSKC will provide coverage for Lemtrada (alemtuzumab) when it is determined to be
More informationLife with MS: Striving for Maximal Independence & Fulfillment
Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain
More informationMULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
More informationResources for the Primary Care Provider. Please print these out for reference
Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical
More informationhttp://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationManaging the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner
Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune
More informationCare Manager Resources: Common Questions & Answers about Treatments for Depression
Care Manager Resources: Common Questions & Answers about Treatments for Depression Questions about Medications 1. How do antidepressants work? Antidepressants help restore the correct balance of certain
More informationNatalizumab (Tysabri)
Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section
More informationWhat is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter
What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted
More informationIntravenous Methyl Prednisolone in Multiple Sclerosis
Intravenous Methyl Prednisolone in Multiple Sclerosis Exceptional healthcare, personally delivered Relapse management in multiple sclerosis Relapses in multiple sclerosis (MS) are common and caused by
More informationThe MS Disease- Modifying Medications
The MS Disease- Modifying Medications National MS Society 1 Current as of January 2015. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication,
More informationReview Date: March 2012. Issue Status: Approved Issue No: 2 Issue Date: March 2010
Title: Multiple Sclerosis guidelines for the use of beta-interferon, glatiramer acetate, natalizumab, mitoxantrone and other disease Authors Name: Dr P Talbot Contact Name: Dr Paul Talbot Contact Phone
More information06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute
The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity
More informationMedication Update. Acknowledgement
Medication Update Multiple Sclerosis Limited Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands we meet today. We acknowledge the deep feelings
More informationPCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15
PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man
More informationResources for the Patient. Please print these out and give them to your patients with MS
Resources for the Patient Please print these out and give them to your patients with MS An internet program for persons with MS on the FCM website Multiple Sclerosis: A Toolbox of Information and Resources
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationNew research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital
New research in primary and secondary progressive multiple sclerosis Huntingdon MS Society Annual Meeting Sat 22nd March 2014 Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital 1 Overview
More informationProduct Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants
Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with
More informationA Letter From the MS Coalition
0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationSt. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor?
St. Luke s MS Center New Patient Questionnaire Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor? Who referred you to the MS Center? List any other doctors you see: Reason you have
More informationSymptom Management in MS. Nancy Fontneau MD Department of Neurology University of Massachusetts
Symptom Management in MS Nancy Fontneau MD Department of Neurology University of Massachusetts Disclosures I have nothing to disclose I will discuss off label use of some medications. Overview Management
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More informationConflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011
Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationUrinary Incontinence FAQ Sheet
Urinary Incontinence FAQ Sheet Are you reluctant to talk to your doctor about your bladder control problem? Don t be. There is help. Loss of bladder control is called urinary incontinence. It can happen
More information